Record overview
Status and phase
Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Condition: Lymphoma, Large B-Cell, Diffuse
NCT05798156
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: primary_completion_date_past_signal | long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.